VERTEX PHARMACEUTICALS INC / MA Net Income
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Net Income of $1.10 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA net income (loss) attributable to parent for the quarter ending 2026-06-30 was $1.10B, a 6.48% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA net income (loss) attributable to parent for the quarter ending 2026-03-31 was $1.03B, a 59.59% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA net income (loss) attributable to parent for the quarter ending 2025-12-31 was $1.19B, a 30.46% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA net income (loss) attributable to parent for the quarter ending 2025-09-30 was $1.08B, a 3.59% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA net income (loss) attributable to parent for fiscal 2025 was $3.95B.
- VERTEX PHARMACEUTICALS INC / MA net income (loss) attributable to parent for fiscal 2024 was -$535.60M, a 114.80% decline from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA net income (loss) attributable to parent for fiscal 2023 was $3.62B, a 8.96% increase from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA net income (loss) attributable to parent for fiscal 2022 was $3.32B, a 41.84% increase from fiscal 2021.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.10B 10-Q · filed 2026-08-04 | $2.13B 10-Q · filed 2026-08-04 | $3.32B derived: sum of 3 quarters · filed 2026-08-04 | $4.41B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $1.03B 10-Q · filed 2026-05-05 | $2.22B derived: sum of 2 quarters · filed 2026-05-05 | $3.31B derived: sum of 3 quarters · filed 2026-05-05 | $4.34B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $1.19B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $2.27B derived: sum of 2 quarters · filed 2026-02-13 | $3.31B derived: sum of 3 quarters · filed 2026-08-04 | $3.95B 10-K · filed 2026-02-13 | ||||
| 2025-09-30 | $1.08B 10-Q · filed 2025-11-04 | $2.12B derived: sum of 2 quarters · filed 2026-08-04 | $2.76B 10-Q · filed 2025-11-04 | $3.68B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $1.03B 10-Q · filed 2026-08-04 | $1.68B 10-Q · filed 2026-08-04 | $2.59B derived: sum of 3 quarters · filed 2026-08-04 | $3.64B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $646.30M 10-Q · filed 2026-05-05 | $1.56B derived: sum of 2 quarters · filed 2026-05-05 | $2.60B derived: sum of 3 quarters · filed 2026-05-05 | -$988.90M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $913.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $1.96B derived: sum of 2 quarters · filed 2026-02-13 | -$1.64B derived: sum of 3 quarters · filed 2026-02-13 | -$535.60M 10-K · filed 2026-02-13 | ||||
| 2024-09-30 | $1.05B 10-Q · filed 2025-11-04 | -$2.55B derived: sum of 2 quarters · filed 2025-11-04 | -$1.45B 10-Q · filed 2025-11-04 | -$479.80M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-06-30 | -$3.59B 10-Q · filed 2025-08-05 | -$2.49B 10-Q · filed 2025-08-05 | -$1.53B derived: sum of 3 quarters · filed 2026-02-13 | -$489.90M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-03-31 | $1.10B 10-Q · filed 2025-05-06 | $2.07B derived: sum of 2 quarters · filed 2026-02-13 | $3.10B derived: sum of 3 quarters · filed 2026-02-13 | $4.02B derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2023-12-31 | $968.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $2.00B derived: sum of 2 quarters · filed 2026-02-13 | $2.92B derived: sum of 3 quarters · filed 2026-02-13 | $3.62B 10-K · filed 2026-02-13 | ||||
| 2023-09-30 | $1.04B 10-Q · filed 2024-11-05 | $1.95B derived: sum of 2 quarters · filed 2024-11-05 | $2.65B 10-Q · filed 2024-11-05 | $3.47B derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-06-30 | $915.70M 10-Q · filed 2024-08-02 | $1.62B 10-Q · filed 2024-08-02 | $2.43B derived: sum of 3 quarters · filed 2025-02-13 | $3.36B derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-03-31 | $699.80M 10-Q · filed 2024-05-07 | $1.52B derived: sum of 2 quarters · filed 2025-02-13 | $2.45B derived: sum of 3 quarters · filed 2025-02-13 | $3.26B derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2022-12-31 | $818.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $1.75B derived: sum of 2 quarters · filed 2025-02-13 | $2.56B derived: sum of 3 quarters · filed 2025-02-13 | $3.32B 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | $930.50M 10-Q · filed 2023-11-07 | $1.74B derived: sum of 2 quarters · filed 2023-11-07 | $2.50B 10-Q · filed 2023-11-07 | $3.27B derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | $810.50M 10-Q · filed 2023-08-02 | $1.57B 10-Q · filed 2023-08-02 | $2.34B derived: sum of 3 quarters · filed 2024-02-15 | $3.19B derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | $762.10M 10-Q · filed 2023-05-02 | $1.53B derived: sum of 2 quarters · filed 2024-02-15 | $2.38B derived: sum of 3 quarters · filed 2024-02-15 | $2.45B derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | $770.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $1.62B derived: sum of 2 quarters · filed 2024-02-15 | $1.69B derived: sum of 3 quarters · filed 2024-02-15 | $2.34B 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | $851.90M 10-Q · filed 2022-10-28 | $851.93M 10-Q · filed 2021-11-03 | $918.90M derived: sum of 2 quarters · filed 2022-10-28 | $1.57B 10-Q · filed 2022-10-28 | $1.57B 10-Q · filed 2021-11-03 | $2.18B derived: sum of 4 quarters · filed 2022-10-28 | ||
| 2021-06-30 | $67.00M 10-Q · filed 2022-08-05 | $66.92M 10-Q · filed 2021-07-30 | $720.10M 10-Q · filed 2022-08-05 | $720.06M 10-Q · filed 2021-07-30 | $1.32B derived: sum of 3 quarters · filed 2022-08-05 | $1.99B derived: sum of 4 quarters · filed 2022-08-05 | ||
| 2021-03-31 | $653.10M 10-Q · filed 2022-05-06 | $653.14M 10-Q · filed 2021-04-30 | $1.26B derived: sum of 2 quarters · filed 2022-05-06 | $1.92B derived: sum of 3 quarters · filed 2022-05-06 | $2.76B derived: sum of 4 quarters · filed 2022-05-06 | |||
| 2020-12-31 | $604.19M 10-K · filed 2021-02-11 | $1.27B derived: sum of 2 quarters · filed 2021-11-03 | $2.11B derived: sum of 3 quarters · filed 2021-11-03 | $2.71B 10-K · filed 2023-02-10 | $2.71B 10-K · filed 2021-02-11 | |||
| 2020-09-30 | $667.43M 10-Q · filed 2021-11-03 | $1.50B derived: sum of 2 quarters · filed 2021-11-03 | $2.11B 10-Q · filed 2021-11-03 | $2.69B derived: sum of 4 quarters · filed 2021-11-03 | ||||
| 2020-06-30 | $837.27M 10-Q · filed 2021-07-30 | $1.44B 10-Q · filed 2021-07-30 | $2.02B derived: sum of 3 quarters · filed 2021-07-30 | $2.08B derived: sum of 4 quarters · filed 2021-07-30 | ||||
| 2020-03-31 | $602.75M 10-Q · filed 2021-04-30 | $1.19B derived: sum of 2 quarters · filed 2021-04-30 | $1.24B derived: sum of 3 quarters · filed 2021-04-30 | $1.51B derived: sum of 4 quarters · filed 2021-04-30 | ||||
| 2019-12-31 | $583.23M 10-K · filed 2021-02-11 | $640.75M derived: sum of 2 quarters · filed 2021-02-11 | $908.18M derived: sum of 3 quarters · filed 2021-02-11 | $1.18B 10-K · filed 2022-02-09 | $1.18B 10-K · filed 2020-02-13 | |||
| 2019-09-30 | $57.52M 10-K · filed 2021-02-11 | $324.94M derived: sum of 2 quarters · filed 2021-02-11 | $593.58M 10-Q · filed 2020-10-30 | $2.14B derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $267.43M 10-K · filed 2021-02-11 | $536.06M 10-Q · filed 2020-07-31 | $2.09B derived: sum of 3 quarters · filed 2021-02-11 | $2.22B derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-03-31 | $268.63M 10-K · filed 2021-02-11 | $1.82B derived: sum of 2 quarters · filed 2021-02-11 | $1.95B derived: sum of 3 quarters · filed 2021-02-11 | $2.16B derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2018-12-31 | $1.55B 10-K · filed 2020-02-13 | $1.68B derived: sum of 2 quarters · filed 2020-02-13 | $1.89B derived: sum of 3 quarters · filed 2020-02-13 | $2.10B 10-K · filed 2021-02-11 | ||||
| 2018-09-30 | $128.75M 10-K · filed 2020-02-13 | $336.11M derived: sum of 2 quarters · filed 2020-02-13 | $546.37M 10-Q · filed 2019-10-31 | $647.05M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-06-30 | $207.36M 10-K · filed 2020-02-13 | $417.62M 10-Q · filed 2019-08-01 | $518.31M derived: sum of 3 quarters · filed 2020-02-13 | $415.36M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-03-31 | $210.26M 10-K · filed 2020-02-13 | $310.95M derived: sum of 2 quarters · filed 2020-02-13 | $208.00M derived: sum of 3 quarters · filed 2020-02-13 | $225.99M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2017-12-31 | $100.68M 10-K · filed 2019-02-13 | -$2.27M derived: sum of 2 quarters · filed 2019-02-13 | $15.73M derived: sum of 3 quarters · filed 2019-02-13 | $263.48M 10-K · filed 2020-02-13 | ||||
| 2017-09-30 | -$102.95M 10-K · filed 2019-02-13 | -$84.96M derived: sum of 2 quarters · filed 2019-02-13 | $162.80M 10-Q · filed 2018-10-25 | $195.75M derived: sum of 4 quarters · filed 2019-02-13 | ||||
| 2017-06-30 | $18.00M 10-K · filed 2019-02-13 | $265.75M 10-Q · filed 2018-07-26 | $298.70M derived: sum of 3 quarters · filed 2019-02-13 | $259.86M derived: sum of 4 quarters · filed 2019-02-13 | ||||
| 2017-03-31 | $247.76M 10-K · filed 2019-02-13 | $280.70M derived: sum of 2 quarters · filed 2019-02-13 | $241.86M derived: sum of 3 quarters · filed 2019-02-13 | $177.34M derived: sum of 4 quarters · filed 2019-02-13 | ||||
| 2016-12-31 | $32.95M 10-K · filed 2018-02-15 | -$5.90M derived: sum of 2 quarters · filed 2018-02-15 | -$70.42M derived: sum of 3 quarters · filed 2018-02-15 | -$112.05M 10-K · filed 2019-02-13 | ||||
| 2016-09-30 | -$38.84M 10-K · filed 2018-02-15 | -$103.37M derived: sum of 2 quarters · filed 2018-02-15 | -$145.00M 10-Q · filed 2017-10-30 | -$218.73M derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2016-06-30 | -$64.53M 10-K · filed 2018-02-15 | -$106.16M 10-Q · filed 2017-07-28 | -$179.89M derived: sum of 3 quarters · filed 2018-02-15 | -$275.04M derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2016-03-31 | -$41.63M 10-K · filed 2018-02-15 | -$115.36M derived: sum of 2 quarters · filed 2018-02-15 | -$210.51M derived: sum of 3 quarters · filed 2018-02-15 | -$399.36M derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2015-12-31 | -$73.73M 10-K · filed 2017-02-23 | -$168.88M derived: sum of 2 quarters · filed 2017-02-23 | -$357.73M derived: sum of 3 quarters · filed 2017-02-23 | -$556.33M 10-K · filed 2018-02-15 | ||||
| 2015-09-30 | -$95.15M 10-K · filed 2017-02-23 | -$284.00M derived: sum of 2 quarters · filed 2017-02-23 | -$482.60M 10-Q · filed 2016-10-31 | -$659.26M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2015-06-30 | -$188.85M 10-K · filed 2017-02-23 | -$387.45M 10-Q · filed 2016-08-01 | -$564.11M derived: sum of 3 quarters · filed 2017-02-23 | -$734.17M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2015-03-31 | -$198.61M 10-K · filed 2017-02-23 | -$375.26M derived: sum of 2 quarters · filed 2017-02-23 | -$545.32M derived: sum of 3 quarters · filed 2017-02-23 | -$704.70M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2014-12-31 | -$176.66M 10-K · filed 2016-02-16 | -$346.72M derived: sum of 2 quarters · filed 2016-02-16 | -$506.10M derived: sum of 3 quarters · filed 2016-02-16 | -$738.55M 10-K · filed 2017-02-23 | ||||
| 2014-09-30 | -$170.06M 10-K · filed 2016-02-16 | -$329.44M derived: sum of 2 quarters · filed 2016-02-16 | -$561.90M 10-Q · filed 2015-10-30 | -$517.61M derived: sum of 4 quarters · filed 2016-02-16 | ||||
| 2014-06-30 | -$159.38M 10-K · filed 2016-02-16 | -$391.84M 10-Q · filed 2015-08-04 | -$347.55M derived: sum of 3 quarters · filed 2016-02-16 | -$471.69M derived: sum of 4 quarters · filed 2016-02-16 | ||||
| 2014-03-31 | -$232.46M 10-K · filed 2016-02-16 | -$188.17M derived: sum of 2 quarters · filed 2016-02-16 | -$312.30M derived: sum of 3 quarters · filed 2016-02-16 | -$369.47M derived: sum of 4 quarters · filed 2016-02-16 | ||||
| 2013-12-31 | $44.28M 10-K · filed 2015-02-13 | -$79.85M derived: sum of 2 quarters · filed 2015-02-13 | -$137.01M derived: sum of 3 quarters · filed 2015-02-13 | -$445.03M 10-K · filed 2016-02-16 | ||||
| 2013-09-30 | -$124.13M 10-K · filed 2015-02-13 | -$181.30M derived: sum of 2 quarters · filed 2015-02-13 | -$489.31M 10-Q · filed 2014-11-06 | -$565.46M derived: sum of 4 quarters · filed 2015-02-13 | ||||
| 2013-06-30 | -$57.16M 10-K · filed 2015-02-13 | -$365.18M 10-Q · filed 2014-07-31 | -$441.33M derived: sum of 3 quarters · filed 2015-02-13 | -$498.87M derived: sum of 4 quarters · filed 2015-02-13 | ||||
| 2013-03-31 | -$308.02M 10-K · filed 2015-02-13 | -$384.16M derived: sum of 2 quarters · filed 2015-02-13 | -$441.71M derived: sum of 3 quarters · filed 2015-02-13 | -$506.64M derived: sum of 4 quarters · filed 2015-02-13 | ||||
| 2012-12-31 | -$76.15M 10-K · filed 2014-02-11 | -$133.69M derived: sum of 2 quarters · filed 2014-02-11 | -$198.62M derived: sum of 3 quarters · filed 2014-02-11 | -$107.03M 10-K · filed 2015-02-13 | ||||
| 2012-09-30 | -$57.54M 10-K · filed 2014-02-11 | -$122.47M derived: sum of 2 quarters · filed 2014-02-11 | -$30.88M 10-Q · filed 2013-11-07 | $127.75M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-06-30 | -$64.93M 10-K · filed 2014-02-11 | $26.66M 10-Q · filed 2013-08-02 | $185.29M derived: sum of 3 quarters · filed 2014-02-11 | $406.40M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-03-31 | $91.59M 10-K · filed 2014-02-11 | $250.22M derived: sum of 2 quarters · filed 2014-02-11 | $471.33M derived: sum of 3 quarters · filed 2014-02-11 | $297.26M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2011-12-31 | $158.63M 10-K · filed 2013-03-01 | $379.74M derived: sum of 2 quarters · filed 2013-03-01 | $205.67M derived: sum of 3 quarters · filed 2013-03-01 | $29.57M 10-K · filed 2014-02-11 | ||||
| 2011-09-30 | $221.11M 10-K · filed 2013-03-01 | $47.04M derived: sum of 2 quarters · filed 2013-03-01 | -$129.06M 10-Q · filed 2012-11-06 | -$309.45M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2011-06-30 | -$174.07M 10-K · filed 2013-03-01 | -$350.17M 10-Q · filed 2012-08-08 | -$530.56M derived: sum of 3 quarters · filed 2013-03-01 | -$739.51M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2011-03-31 | -$176.10M 10-K · filed 2013-03-01 | -$356.49M derived: sum of 2 quarters · filed 2013-03-01 | -$565.45M derived: sum of 3 quarters · filed 2013-03-01 | -$765.45M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2010-12-31 | -$180.39M 10-K · filed 2012-02-22 | -$389.35M derived: sum of 2 quarters · filed 2012-02-22 | -$589.36M derived: sum of 3 quarters · filed 2012-02-22 | -$754.63M 10-K · filed 2013-03-01 | ||||
| 2010-09-30 | -$208.96M 10-K · filed 2012-02-22 | -$408.96M derived: sum of 2 quarters · filed 2012-02-22 | -$574.23M 10-Q · filed 2011-11-03 | |||||
| 2010-06-30 | -$200.01M 10-K · filed 2012-02-22 | -$365.28M 10-Q · filed 2011-08-09 | ||||||
| 2010-03-31 | -$165.27M 10-K · filed 2012-02-22 | |||||||
| 2009-12-31 | -$642.18M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |